<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227539</url>
  </required_header>
  <id_info>
    <org_study_id>6228</org_study_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>UWCC-6228</secondary_id>
    <secondary_id>UWCC-UW-6228</secondary_id>
    <secondary_id>UW-04033</secondary_id>
    <secondary_id>LILY-UW-04033</secondary_id>
    <secondary_id>CDR0000441239</secondary_id>
    <nct_id>NCT00227539</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before,
      during, and after chemotherapy) may help doctors predict a patient's response to treatment
      and help plan the best treatment. Drugs used in chemotherapy, such as pemetrexed disodium and
      cisplatin, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Giving combination chemotherapy after surgery may
      kill any tumor cells that remain after surgery.

      PURPOSE: This phase II trial is studying how well PET works in predicting response in
      patients who are undergoing treatment with pemetrexed disodium and cisplatin with or without
      surgery for stage I, stage II, or stage III non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the effectiveness of fludeoxyglucose F 18 positron emission tomography in
           predicting radiological and pathological response in patients treated with pemetrexed
           disodium and cisplatin with or without surgery for stage IB-IIIB non-small cell lung
           cancer (NSCLC).

      Secondary

        -  Determine the safety of cisplatin and pemetrexed disodium in these patients.

        -  Determine the radiographic response rate, duration of response, and time to progression
           in patients treated with cisplatin and pemetrexed disodium.

      OUTLINE: This is a multicenter study.

        -  Fludeoxyglucose F 18 (18FDG) positron emission tomography (PET) imaging: All patients
           undergo positron emission tomography (PET) imaging of the head, neck, thorax, abdomen,
           and pelvis. Patients receive fludeoxyglucose F 18 (^18FDG) IV followed by 45 minutes of
           rest. PET imaging is done over 1 hour and 8 minutes. Patients undergo PET imaging at
           three points during the study: 4 weeks prior to treatment, after the first cycle of
           treatment, and after 3 courses of chemotherapy. Some patients then undergo surgical
           resection of the tumor.

        -  Chemotherapy: Patients receive cisplatin IV over 30 minutes and pemetrexed disodium IV
           over 10 minutes on day 1. Courses repeat every 21 days for up to 3 courses in the
           absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then every 6 months for 3 years.

      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy</measure>
    <time_frame>Between days 18 and 22 prior to second chemotherapy infusion</time_frame>
    <description>Number of Participants with Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Neoadjuvant Chemotherapy</measure>
    <time_frame>Up to 4 weeks after last dose of chemotherapy</time_frame>
    <description>The number of patients that experienced a grade 3 or higher adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate</measure>
    <time_frame>Up to 4 weeks after last dose of chemotherapy</time_frame>
    <description>The number of patients that had either a CR, PR or SD after the completion of chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant therapy, PET scan and surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Neoadjuvant therapy, PET scan and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
    <arm_group_label>Neoadjuvant therapy, PET scan and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Neoadjuvant therapy, PET scan and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Neoadjuvant therapy, PET scan and surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <arm_group_label>Neoadjuvant therapy, PET scan and surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

          -  Stage IB, II, IIIA, or IIIB (T4, N0-1) disease

               -  Staging must have been performed 4 weeks prior to study entry with a CT scan of
                  chest, upper abdomen, and fludeoxyglucose F 18 (^18FDG) positron emission
                  tomography (PET) scan

               -  Mediastinal evaluation and staging based on combination of CT scan and FDG-PET
                  results

          -  If N1 or N2 nodes are found by FDG-PET or CT scan, metastases must be ruled out by
             brain MRI

          -  Measurable and resectable disease

               -  T4 lesions must be resectable

          -  Eligible for curative surgery

          -  No malignant pleural effusion

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,250/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST and ALT ≤ 3.0 times ULN

        Renal

          -  Creatinine clearance ≥ 45 mL/min

        Pulmonary

          -  Adequate pulmonary reserve to undergo surgery

               -  Predicted FEV_1 &gt; 0.8 L after resection

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  Able to take corticosteroids

          -  Able to take folic acid or vitamin B_12 supplements

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             noninvasive cervical cancer

          -  No concurrent serious or uncontrolled disorder that would preclude study participation

          -  No type I diabetes mellitus

               -  Type II diabetes mellitus allowed if glucose is 80-150 mg/dL

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

          -  No concurrent prophylactic filgrastim (G-CSF)

          -  No concurrent thrombopoiesis-stimulating agents

        Chemotherapy

          -  At least 5 years since prior chemotherapy

        Endocrine therapy

          -  No concurrent anticancer hormonal therapy

        Radiotherapy

          -  No prior radiotherapy to the chest

          -  No concurrent curative or palliative radiotherapy

        Surgery

          -  Not specified

        Other

          -  At least 30 days since prior non-FDA-approved or investigational agents

          -  At least 5 days since prior aspirin or other nonsteroidal anti-inflammatory agents (8
             days for long-acting agents [e.g., piroxicam])

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato Martins, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>February 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Renato Martins</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Neoadjuvant Therapy, PET Scan and Surgery</title>
          <description>cisplatin
pemetrexed disodium
adjuvant therapy
therapeutic conventional surgery
fludeoxyglucose F 18</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Neoadjuvant Therapy, PET Scan and Surgery</title>
          <description>cisplatin
pemetrexed disodium
adjuvant therapy
therapeutic conventional surgery
fludeoxyglucose F 18</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="47" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy</title>
        <description>Number of Participants with Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy</description>
        <time_frame>Between days 18 and 22 prior to second chemotherapy infusion</time_frame>
        <population>Only 19 patients had PET scans at both baseline and day 18-22 available for review.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Therapy, PET Scan and Surgery</title>
            <description>cisplatin
pemetrexed disodium
adjuvant therapy
therapeutic conventional surgery
fludeoxyglucose F 18</description>
          </group>
        </group_list>
        <measure>
          <title>Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy</title>
          <description>Number of Participants with Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy</description>
          <population>Only 19 patients had PET scans at both baseline and day 18-22 available for review.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Neoadjuvant Chemotherapy</title>
        <description>The number of patients that experienced a grade 3 or higher adverse event.</description>
        <time_frame>Up to 4 weeks after last dose of chemotherapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Therapy, PET Scan and Surgery</title>
            <description>cisplatin
pemetrexed disodium
adjuvant therapy
therapeutic conventional surgery
fludeoxyglucose F 18</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Neoadjuvant Chemotherapy</title>
          <description>The number of patients that experienced a grade 3 or higher adverse event.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate</title>
        <description>The number of patients that had either a CR, PR or SD after the completion of chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.</description>
        <time_frame>Up to 4 weeks after last dose of chemotherapy</time_frame>
        <population>One patient was excluded from the efficacy analysis because they were subsequently found to be ineligible. Three patients were unevaluable because they did not have have a CT scan after the completion of chemotherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Neoadjuvant Therapy, PET Scan and Surgery</title>
            <description>cisplatin
pemetrexed disodium
adjuvant therapy
therapeutic conventional surgery
fludeoxyglucose F 18</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate</title>
          <description>The number of patients that had either a CR, PR or SD after the completion of chemotherapy. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.</description>
          <population>One patient was excluded from the efficacy analysis because they were subsequently found to be ineligible. Three patients were unevaluable because they did not have have a CT scan after the completion of chemotherapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of first dose of chemotherapy through 4 weeks following the final dose of chemotherapy.</time_frame>
      <desc>Only grade 3 and higher adverse events were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Neoadjuvant Therapy, PET Scan and Surgery</title>
          <description>cisplatin
pemetrexed disodium
adjuvant therapy
therapeutic conventional surgery
fludeoxyglucose F 18</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="25" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Reaction</sub_title>
                <counts group_id="E1" events="25" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="25" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Renato G. Martins</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-288-6680</phone>
      <email>rgmart@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

